LAM Pilot Study with Imatinib Mesylate (LAMP-1)

Abstract

The LAMP-1 study is designed to generate short-term safety and efficacy data regarding imatinib mesylate (imatinib) in the treatment of Lymphangioleiomyomatosis (LAM) sufficient to power and design a phase 3 imatinib vs. placebo clinical trial. The hypothesis is that imatinib will be equivalent to rapamycin in short term efficacy and safety. Currently, most LAM patients are treated with rapamycin, which growth-inhibits but does not kill LAM cells. In the laboratory of Dr. DArmiento, imatinib was shown to completely block the growth of LAM cells through initiation of targeted cell death. This study employs a small clinical trial design using 20 participants at two institutions. 10 participants will be enrolled at Medical University of South Carolina and 10 at Columbia University. Importantly, VEGF-D level will be used to monitor LAM disease activity and therapeutic response.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1004102

Entities

People

  • Charlie Strange

Organizations

  • Medical University of South Carolina

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Cell Physiological Processes
  • Cells
  • Clinical Trials
  • Data Analysis
  • Governments
  • Institutional Review Board
  • Local Governments
  • Patent Applications
  • Pilot Studies
  • Professional Development
  • South Carolina
  • Students
  • Therapy
  • Training
  • Universities

Readers

  • Aquatic Ecology
  • Breast cancer cell signaling and growth regulation.
  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.